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Hydrogen sulfide (H2S), a gaseous molecule is known to be 
synthesized endogenously in the mammalian tissues from the 
amino acid l-cysteine. Although considered as an environ-
mental toxic gas, endogenously produced H2S is now appre-
ciated as gaseous signalling molecule alongside nitric oxide 
(NO) and carbon monoxide that modulates many physiologi-
cal functions of the human body at molecular and systemic 
levels.1 It is generated mainly by the action of two tissue spe-
cific enzymes named cystathionine γ-lyase (CGL) and cys-
tathionine β-synthase (CBS) on the substrate l-cysteine. At 
present, the distribution of CGL and CBS throughout the body 
is not well characterized. However, it is reported that CGL is 
the major H2S producing enzyme in the cardiovascular sys-
tem and is present in the vascular smooth muscle as well as the 
endothelium.2,3 On the other hand, CBS is mainly present in 
nervous tissues; although, its presence is also reported in many 
vascular  tissues.4  Recently,  it  has  also  been  suggested  that 
another enzyme, 3-Mercaptopyruvate sulfurtransferase, which 
is specifically localized to neuronal tissue, is also involved in 
the generation of this gaseous molecule in the brain.5 However, 
only CGL and CBS enzymes are mainly present in liver and 
kidney tissues that are important for not only the metabolism 
of sulfur containing amino acids, but also the production of 
H2S, which may exert various functions in different tissues.6
Recent studies have implicated an important role for endo-
genously formed H2S as a critical regulator of cardiovascular 
homeostasis. H2S has been characterized as autocrine/para-
crine messenger implicated in the control of vascular tone. It 
has been demonstrated that H2S-donor compound, sodium 
hydrogen  sulfide  (NaHS),  causes  dose-dependent  relaxa-
tions  of  the  isolated  rat  aorta2,7,8  and  mesenteric  arteries.9 
Administration of NaHS, both acutely and chronically, caused 
reduction  in  blood  pressure  in  hypertensive  rats  induced 
by  NO  synthase  inhibition.10  However,  conflicting  findings 
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Background
Hydrogen sulfide (H2S), an endogenous vasoactive agent, is 
produced by cystathionine γ-lyase (CGL) and cystathionine 
β-synthase (CBS) enzymes. This study was conducted to evaluate the 
relative contribution of these enzymes in regulating systemic arterial 
pressure.
Methods
Sprague–Dawley rats were chronically treated with CGL inhibitor, 
d l-propargylglycine (PaG, 37.5 mg/kg/day; intraperitoneally, i.p.) or 
CBS inhibitor, aminooxyacetic acid (aOa, 8.75 mg/kg/day; i.p.) or in 
combination for 4 weeks and the effects on arterial pressure (tail-cuff 
plethysmography) and renal excretory function (24 h urine collections 
using metabolic cages) were assessed once in a week. Changes in 
renal blood flow (rBF; ultrasonic flowmetry) and glomerular filtration 
rate (GFr; Inulin clearance) were assessed in acute experiments in 
anesthetized rats at the end of treatment period.
results
Compared to vehicle treated control group, only the rats with 
combination therapy showed a decrease in urinary sulfate excretion 
rate (248 ± 47 vs. 591 ± 70 nmol/24 h; marker for endogenous H2S 
level) which was associated with an increase in mean arterial pressure 
(MaP; 130 ± 2 vs. 99 ± 2 mm Hg). urine flow and sodium excretion 
were also increased in combination group as consequent to the 
increase in MaP. GFr did not alter due to these treatments but rBF 
was lowered (4 ± 0.3 vs. 7 ± 0.4 ml/min/g) only in the combination 
group compared to the control group.
conclusion
These findings indicate that a deficiency in one enzyme’s activity 
could be compensated by the activity of the other to maintain the 
endogenous H2S level, the deficiency of which modulates systemic 
and renal vascular resistances leading to the development of 
hypertension.
Keywords: aminooxyacetic acid; blood pressure; d l-propargylglycine; 
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were reported in mice with disrupted CGL enzyme as it was 
observed in one study3 that CGL knock-out mice developed 
hypertension after seventh week of age but other study11 have 
shown that such knock-out mice were usually normotensive. 
Although it is generally accepted that the action of CGL in the 
cardiovascular system is responsible for the effect of H2S on 
cardiovascular function, the activity of CBS may also play an 
important role in modulating vascular tone via its effects on 
autonomic nervous system.12 It is reported that H2S is criti-
cal in maintaining the excitatory/inhibitory balance in neu-
rotransmission and thus serves as a novel neuromodulator.13 
Although no specific mechanism has yet been identified, it 
may be possible that H2S exerts an inhibitory effect on sym-
pathetic nerve activity and thus modulates vascular tone to 
maintain blood pressure homeostasis.12 However, the relative 
contribution of CGL- and CBS-mediated production of H2S 
in the regulation of blood pressure and the deficiency of their 
activities in the pathophysiology of hypertension is not yet 
clearly known.
We  hypothesized  that  as  CGL  enzyme  is  present  mostly 
in the vascular tissue, H2S production induced by the CGL 
activity would play a more predominant role in the regula-
tion of systemic blood pressure compared to the activity of 
CBS which is primarily located in the nervous tissue. In this 
study, we examined the effects of chronic administration of 
the inhibitors of CGL (dl-propargylglycine; PAG)14 and CBS 
(aminooxyacetic acid; AOA)6 in rats for a 4-week period to 
determine the relative contribution of these enzymes in regu-
lating blood pressure. As the kidney plays a key-regulatory role 
in maintaining systemic blood pressure, the effects of chronic 
inhibition of CGL and CBS on renal hemodynamic and excre-
tory function are also assessed in this study.
Methods
All of the experimental procedures described in this study were 
approved by and performed in accordance with the guidelines 
and  practices  established  by  the  Tulane  University  Animal 
Care and Use Committee. These experiments were conducted 
on  male  Sprague–Dawley  rats  weighing  250–300 g  body 
weight (8 week-old) that were purchased from Charles River 
Laboratories (Wilmington, MA), housed in a temperature- and 
light-controlled room in the Tulane University Vivarium, and 
allowed free access to a standard diet and tap water. The rats 
were divided into four groups (n = 6 in each group) according 
to chronic drug treatment as described below:
The doses of PAG (37.5 mg/kg/day i.p.) and AOA (8.75 mg/
kg/day i.p.) for chronic daily injections were considered as 
these doses were calculated based on the assumption that the 
injected would be completely absorbed into the blood circu-
lation and reach a circulating concentration around 5 mmol/l 
and 1 mmol/l for PAG and AOA respectively. These concentra-
tions were shown to cause maximal inhibitory effect on H2S 
production in vitro in rat aortic14 and in liver tissue.6 These 
rats were exposed to the experimental procedures for a week 
prior to the beginning of the actual experiments in order to 
minimize the effects of environmental and procedural stresses 
on the experimental results. Both chronic studies at the con-
scious state and acute experiments under anesthesia at the end 
of chronic experimental periods were performed in these rats.
Chronic experiments. In the chronic studies, blood pressure 
was measured using tail-cuff plethysmography, and 24-h urine 
collections were made using metabolic cages in conscious rats. 
Baseline blood pressure and urine collections were obtained 
on the day prior to the start of daily drug treatment. During 
the 4-week treatment period, blood pressure and 24-h urine 
collections were made at the end of each week. On each occa-
sion, blood pressure was measured first and then the rats were 
placed in metabolic cages for 24 h for urine collections. After 
noting the volume of urine-output, all urine samples were kept 
frozen (−20 °C) until analyzed for sulfate, sodium, and potas-
sium concentrations in the urine.
Acute experiments. At the end of the 4-week chronic experi-
mental period, the rats were anesthetized with thiobutabarbi-
tal sodium (Inactin; Sigma-Aldrich, St Louis, MO) at a dose of 
100 mg/kg i.p. Supplemental doses of anesthesia were adminis-
tered throughout the experimental period as required. The rats 
were placed on a servo-controlled surgical table that maintained 
body temperature at 37 °C. Tracheostomy was performed, and 
the animals were continuously provided with a mixture of 95% 
O2 and 5% CO2 through the endotracheal tube (PE-200).15 The 
right jugular vein was cannulated for the intravenous adminis-
tration of an isotonic saline solution containing 1% albumin and 
7.5% inulin (Inutest, Laevosan, Linz/Donau, Austria) as well as 
for supplemental doses of anesthesia. The right femoral artery 
was  catheterized,  and  the  cannula  was  connected  to  a  pres-
sure transducer to allow for continuous monitoring of arterial 
blood pressure using the AcqKnowledge data acquisition system 
(Biopac). The left kidney was exposed via a left-flank incision 
and placed in a lucite cup, and the left ureter was cannulated 
with a PE-10 catheter for urine collection. An ultrasonic flow 
probe (Transonic System) was placed on the left renal artery 
to measure total renal blood flow (RBF).15 Laser-Doppler flow 
probes (500 µm OD, Periflex 4001; Perimed) were used to meas-
ure the regional blood flow in the kidney.15,16 Cortical blood 
flow was measured by a Laser-Doppler flow probe placed on 
the surface of the kidney, and medullary blood flow was meas-
ured  by  a  needle  Laser-Doppler  flow  probe  inserted  ~3 mm 
deep into the left kidney. After a 60-min equilibration period 
following completion of surgical procedures, urine collections 
for two consecutive 30-min clearance periods were made with 
collections of corresponding blood samples and recordings of 
Group 1 Control Vehicle (saline) treated
Group 2 PaG Treated with PaG (37.5 mg/kg/day 
intraperitoneally, i.p.) alone
Group 3 aOa Treated with aOa (8.75 mg/kg/day i.p.)  
alone
Group 4 PaG + aOa Treated with both PaG and aOa76     January 2012 | VOLuME 25 nuMBEr 1 | AMERICAN JOURNAL OF HYPERTENSION
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  hemodynamic parameters. All blood and urine samples were 
kept frozen (−20°C) until analyzed for concentrations of inulin.
Measurement of proteins level and expressions of CGL and CBS 
in the renal tissue. At the end of the experiments, 29 or 30 days 
following the start of the treatment with inhibitors, rats were 
killed and the right kidneys were sagittally sectioned to use one 
half fixed in formalin for immunohistochemistry for localiza-
tion CGL and CBS proteins in the renal tissues, and the other 
half was snap-frozen for eventual western blot analysis. CGL 
and  CBS  immunohistochemistry  were  performed  in  forma-
lin fixed renal tissue sections (3 µm) by peroxidase technique 
using  specific  antibodies  for  CGL  (cat  no  H00001434-M01; 
Abnova) and CBS (cat no H00000875-M01; Abnova) respec-
tively at 1:3,000 and 1:500 dilutions to determine the distribu-
tion of the specific proteins and their changes during chronic 
treatments with PAG and AOA. Semi-quantitation of immu-
noreactivity was performed using NIS Elements AR version 3.0 
software; (Nikon). In addition, whole kidney samples were used 
to measure CGL and CBS protein levels by western blot. The 
proteins were electrophoretically transferred to a nitrocellulose 
membrane (Invitrogen, Carlsbad, CA) using iBlot (Invitrogen), 
blocked with Odyssey blocking buffer (LI-COR Biosciences, 
Lincoln,  NE)  followed  by  the  incubation  overnight  at  4 °C 
with the primary antibodies mouse anti-CGL (1:500 dilution) 
and mouse anti-CBS (1:1,000 dilution). Detection was accom-
plished using an Odyssey fluorescent scanner.
Analytical procedures for blood and urine samples and statisti-
cal analysis. Urinary excretion rate of sulfate (USV) is deter-
mined by analyzing urine samples acquired from the chronic 
experiments using Zinc-trapping and colorimetry method.17,18 
The changes in USV are considered as an indicator for assess-
ing the status of endogenous H2S production in the animals 
used in this study. The concentrations of sodium and potas-
sium in urine samples were determined by flame-photometry. 
Spectrophotometry was used to determine inulin levels in the 
urine and blood samples obtained during the acute experi-
ment. The value of inulin clearance was considered as glomer-
ular filtration rate (GFR). Data are expressed as means ± SE. 
Statistical comparisons of differences in means were done by 
one-way  ANOVA  followed  by  Holm-Sidak  post  hoc  t-tests. 
Differences in the mean values were deemed significant at P 
< 0.05.
results
effect of chronic Pag and aoa treatment on usV
These effects are summarized in Figure 1. Inhibition of CGL 
or CBS by chronic treatments of PAG or AOA alone had no 
significant effect on USV. However, the combination therapy of 
these inhibitors resulted in significant decreases in USV after 
the second week of treatment period (240 ± 18 vs 591 ± 70 
nmol/24 h; P < 0.05) compared to values at day 0 (D0) which 
remains unaltered on the fourth week of treatment (248 ± 
50 nmol/24 h; P < 0.05). This finding indicated that the dose 
of combination therapy was effective in causing substantial 
inhibition (>50%) of endogenous H2S production. Although 
changes in USV is considered as an indicator for assessing the 
changes in endogenous H2S production, it should be noted 
here that USV may also represent the dietary and other meta-
bolic sources of sulfur.19 However, as it was ensured that the 
animals of similar age and sex in different groups were given 
identical diet and housed in identical condition, the contribu-
tion of other sources of sulfur was deemed minimal in causing 
the observed changes in USV.
effect of chronic treatment of Pag and aoa on mean arterial 
blood pressure
The changes in mean arterial pressure (MAP) in each group of 
rats are illustrated in Figure 2. It was observed that the treat-
ment with PAG or AOA alone for 4 weeks did not alter MAP 
in rats. However, in the group of rats that were treated with 
combination therapy of both PAG and AOA, MAP increased 
gradually from 99 ± 2 mm Hg at D0 to 130 ± 1 mm Hg (P < 
0.05) at the end of 4-week treatment period. However, signifi-
cant difference was noted at the end of third week (130 ± 2; 
P < 0.05) but not at the end of second week (114 ± 5 mm Hg; 
P = n.s.) treatment period when compared to the values at D0. 
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Figure 1 | urinary excretion rate of sulfate (uSV) responses to chronic 
inhibition of H2S production (data from the chronic experiments). PaG, 
d l-propargylglycine (CGL inhibitor); aOa, aminooxyacetic acid (CBS 
inhibitor). *P < 0.05 vs. values on day 0 (D0). aOa, aminooxyacetic acid; CBS, 
cystathionine β-synthase; CGL, cystathionine γ-lyase; PaG, d l-propargylglycine.
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Figure 2 | Mean blood pressure (MBP) responses to chronic inhibition of H2S 
production (data from the chronic experiments). *P < 0.05 vs. values on day 0 
(D0). aOa, aminooxyacetic acid (CBS inhibitor); CBS, cystathionine β-synthase; 
CGL, cystathionine γ-lyase; PaG, d l-propargylglycine (CGL inhibitor).AMERICAN JOURNAL OF HYPERTENSION | VOLuME 25 nuMBEr 1 | January 2012     77
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It was noted that the changes in USV (significant changes at 
the end of second week) were preceded the changes in MAP 
(significant changes at the end of third week).
effects of chronic treatment of Pag and aoa on urine flow,  
urinary excretion of sodium and potassium
The  results  of  these  measurements  are  summarized  in 
Figures 3 and 4. Urine flow (V; Figure 3), urinary excre-
tion  rate  of  sodium  (UNaV;  Figure  4)  and  urinary  excre-
tion of potassium did not alter during treatment of PAG or 
AOA alone. However, in the combined therapy group, V was 
increased gradually from 12.7 ± 0.8 ml/day on D0 to 38.8 ± 
5.4 ml/day (P < 0.05) at the fourth week treatment period. 
Similar to the response on V, urinary excretion rate of sodium 
(UNaV; Figure 4) were also increased in combination therapy 
group. UNaV was increased gradually from 3.6 ± 0.5 mmol/day 
on D0 to 13.4 ± 3.1 mmol/day (P < 0.05) at the fourth week 
treatment period. However, the changes in urinary excretion 
of potassium during combination therapy were not statisti-
cally different during the treatment period (2.4 ± 0.2 mmol/
day on D0 to 3.2 ± 0.3, 5.1 ± 0.7, 4.5 ± 0.4, and 4.3 ± 1.2 mmol/
day at the end of first, second, third, and fourth week period 
of treatment respectively.)
effects of chronic treatment of Pag and aoa on renal blood 
flow and glomerular filtration rate
The results obtained from acute experiments at the end of 4-week 
treatment period, are provided in Table  1. The total RBF was 
significantly lower in rats with combination therapy compared 
to that in the vehicle treated group as well as in groups treated 
with PAG or AOA alone. Similarly, regional blood flow (cortical 
blood flow and medullary blood flow) was also lower in the com-
bination therapy group compared to the values in other groups. 
However, the values of GFR were not significantly different in any 
of these treatment groups compared to the vehicle treated group.
immunohistochemistry analysis of cgl and cBs  
in renal tissues
CGL and CBS immunoreactivity and densitometric analysis in 
kidney slices are illustrated in Figure 5 and Figure 6, respec-
tively. As illustrated in Figure 5a, CGL was mainly located 
in renal vasculature as well as in distal nephron segments in 
tissues taken vehicle treated control rats. Mean data from the 
densitometric analysis of the intensity of CGL immunoreactiv-
ity in these kidney sections are illustrated in Figure 5e. It was 
observed that CGL immunoreactivity increased nearly three-
fold in PAG treated rats and nearly twofold in rats subjected to 
combination therapy compared to vehicle treated group. This 
enhancement in CGL immune-expression in combined treat-
ment group was significantly lower than that in PAG treated 
group. There was no change in CGL intensity in AOA treated 
group. On the other hand, CBS immunostaining was observed 
exclusively in intracellular compartment of proximal tubular 
cells in control rats (Figure 6a). Similar distribution, though 
with markedly increased immunointensity, was observed in 
kidney sections from rats treated with combination therapy. 
It  should  be  noted  that  CBS  immunoreactivity  was  mainly 
observed at the brush border but not intracellularly in the 
proximal tubular cells in rats treated with either PAG or AOA 
alone. This CBS immunoreactivity was absent in the glomer-
uli and other tubular segments as well as in renal vasculature. 
Mean data from the densitometric analysis of the CBS inten-
sity in these kidney sections are illustrated in Figure 6e. CBS 
immunoreactivity was slightly but significantly increased in 
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Figure 4 | urinary excretion rate of sodium (unaV) responses to chronic 
inhibition of H2S production (data from the chronic experiments); *P < 0.05 
vs. values on day 0 (D0). aOa, aminooxyacetic acid (CBS inhibitor); 
CBS, cystathionine β-synthase; CGL, cystathionine γ-lyase; PaG, d l-
propargylglycine (CGL inhibitor).
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Figure 3 | urine flow (V) responses to chronic inhibition of H2S production 
(data from the chronic experiments). *P < 0.05 vs. values on day 0 (D0). aOa, 
aminooxyacetic acid (CBS inhibitor); CBS, cystathionine β-synthase; CGL, 
cystathionine γ-lyase; PaG, d l-propargylglycine (CGL inhibitor).
table 1 | renal hemodynamic parameters after 4 weeks of h2s 
inhibition (data from the acute experiments).
Treatment groups
RBF
(ml/min/g)
GFR
(ml/min/g)
CBF
(PU)
MBF
(PU)
Control (n = 6) 7.0 ± 0.4 1.0 ± 0.05 554 ± 15 232 ± 36
PaG (n = 6) 7.0 ± 1.2 0.94 ± 0.06 476 ± 21 175 ± 38
aOa (n = 5) 7.2 ± 1.0 0.91 ± 0.03 485 ± 48 218 ± 39
aOa + PaG (n = 5) 3.5 ± 1.2* 0.92 ± 0.04 375 ± 26* 134 ± 19
AOA, aminooxyacetic acid; CBF, cortical blood flow; GFR, glomerular filtration rate;   
MBF, medullary blood flow; PAG, d l -propargylglycine; PU, perfusion unit; RBF, renal blood 
flow. *P < 0.05 vs. values in control group.78     January 2012 | VOLuME 25 nuMBEr 1 | AMERICAN JOURNAL OF HYPERTENSION
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combination therapy group compared to PAG alone treated 
group.
Western blot analysis of cgl and cBs in renal tissue
Further quantification of the levels of these enzyme proteins 
in the renal tissues by western blot analysis revealed that PAG 
and PAG plus AOA treatments significantly increased CGL 
protein levels (25 kDa)20 in whole kidney samples compared 
to controls (PAG: 3.0 ± 0.3; PAG + AOA: 1.7 ± 0.4 vs. control: 
1.0 ± 0.1-fold change; P < 0.01; n = 4 in each cases) but not 
AOA alone (1.0 ± 0.1) (Figure 7a). In contrast, these treat-
ments did not alter the protein levels of CBS (63 kDa)21 in the 
kidney (PAG: 0.7 ± 0.04; AOA: 1.1 ± 0.3; PAG + AOA: 0.8 ± 
0.1; vs. control: 1.0 ± 0.1-fold change; P = 0.02; n = 4 in each 
cases) (Figure 7b). These results of the protein levels quanti-
fied by western blot were comparable with those observed with 
immunohistochemistry analysis as above.
discussion
In  the  present  investigation,  we  have  demonstrated  that 
chronic  administration  of  the  inhibitors  of  both  CGL  and 
CBS enzymes in combination for 4 weeks in rats resulted in a 
decrease in USV which is considered as an indicator for endog-
enous H2S production. Although the doses of these inhibitors 
independently were shown to be effective in preventing H2S 
generation in rat aortic14 and liver6 tissues, the level of USV 
was not altered by these doses when given individually in this 
study. The changes in USV were also associated with increases 
in MAP in the combination therapy group. It was noted that 
the changes in USV (at the second week) preceded the changes 
in MAP (at the third week) indicating that a deficiency in H2S 
production leads to an increase in arterial pressure. These find-
ings demonstrate that the reduction in H2S production in the 
vascular system occurred only when activities of both H2S pro-
ducing enzymes (CGL and CBS) were simultaneously blocked. 
These results suggest that the deficiency in the activity of one 
enzyme could be compensated by the activity of the other in 
maintaining the endogenous production level of H2S.
Although  USV  or  blood  pressure  did  not  alter  during  4 
weeks of treatment with PAG alone in this study, the same 
dose administration of this CGL inhibitor in a previous study 
in rats14 reported a reduction in plasma level of H2S and asso-
ciated increase in blood pressure at the end of more than 5 
weeks  treatment  period.  This  apparent  discrepancy  seems 
related to the difference in the period of treatment with the 
inhibitor. CGL expressions in the renal tissue were also not 
reduced  (rather  increased)  during  4-week  period  of  PAG 
treatment in the present study. However, the results from the 
previous study14 indicate that CGL expression as well as the 
reductions in tissue and plasma H2S levels in the aortic tissue 
was decreased only after 5-week period of treatment with the 
enzyme inhibitor. These results may indicate a time depend-
ency of this inhibitor’s ability on reducing endogenous H2S 
production that contributes to increase in arterial pressure. 
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It is also noted that a considerable time-delay exists in medi-
ating the response to a deficiency in CGL activity and the 
consequent increases in blood pressure. The knock-out mice 
lacking the gene for CGL usually not hypertensive at early 
age3,11 but developed hypertension after at least after 7 weeks 
of age.3
A link between H2S deficiency and an increase in arterial 
pressure has been suggested in many previous studies.10,22,23 
A deficient level of plasma H2S was reported in hypertensive 
rat models such as SHR when compared to the level in normo-
tensive WKY rat models.14 Hypertension induced by treatment 
with NO synthase inhibitors in rats was also associated with a 
decrease in plasma H2S level.10 On the other hand, systemic 
administration of the H2S-donor compound NaHS resulted 
in hypotension in many previous studies.7,10,23 In one study, 
it was reported that the genetic deletion of CGL enzymes in 
mice resulted in nearly 50% reduction in the plasma level of 
H2S, which was associated with ~20–25 mm Hg increases in 
MAP.3 In the present study in rats, we also observed compa-
rable changes in MAP (~25 mm Hg) in response to combina-
tion therapy with PAG and AOA that resulted in nearly a 50% 
reduction in USV, indicating a similar reduction in the plasma 
level of H2S in rats as reported in earlier studies on mice.3
The cardiovascular effects of H2S have been demonstrated 
in  experimental  studies  in  vivo10  and  in  vitro.2,7–9  Most  of 
these  studies  provided  evidence  that  H2S  is  a  novel  gase-
ous  vasorelaxant  agent,  acting  by  directly  increasing  KATP 
  channel   currents and hyperpolarizing the cellular membrane.7 
However, as opposed to other gaso-transmitters such as NO 
and  carbon  monoxide,  H2S-induced  vasorelaxation  is  not 
mediated by the cyclic guanosine 3ʹ,5ʹ-monophosphate sign-
aling pathway, but rather by the cyclic adenosine 3ʹ,5ʹ-mono-
phosphate signaling pathway.24–26 It is suggested that H2S is 
acting as a putative endothelium dependent hyperpolarizing 
factor, thus reducing the extracellular Ca2+ entry and relaxing 
vascular smooth muscle cells.27 Although acting as a vasore-
laxant, H2S also caused inhibition of vascular smooth muscle 
cells’ proliferation and induced apoptosis in some in vitro stud-
ies.28,29  Thus,  a  generalized  vasoconstriction  and  structural 
remodeling by vascular smooth muscle cells’ proliferation may 
be involved in the hypertensive response to the chronic H2S 
deficiency in the present study.
Associated  with  increases  in  MAP  in  the  present  study, 
there were also reductions in total RBF and regional blood 
flow (cortical blood flow and medullary blood flow) in the 
kidney due to this combination therapy, demonstrating that 
the reduction in H2S formation resulted in increases in sys-
temic as well as in renal vascular resistances. In the present 
study, there was no appreciable change in GFR though RBF 
decreased in rats chronically treated with combined admin-
istration of PAG and AOA. This indicates that there were pro-
portionate reductions in vascular resistances in both afferent 
Control
C
B
S
 
i
m
m
u
n
o
r
e
a
c
t
i
v
i
t
y
-
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
0.0
0.5
1.0
1.5 e
PAGA OA PAG + AOA
*
abcd
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with marked increased immunointensity, was observed in kidney sections from rats treated with combination (PaG + aOa) therapy (panel d). It should be noted 
that CBS immunoreactivity was mainly observed at the brush border but not intracellularly in the PT cells in rats treated either PaG (panel b) or aOa (panel c) 
alone. Glomeruli, other tubular segments and renal vasculature were negative. Mean data from the densitometric analysis of the CBS intensity in these kidney 
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and efferent arterioles during chronic combination therapy 
that maintained the net glomerular pressure at a steady state30 
and thus, GFR remains unchanged. The increases in urine 
flow and sodium excretion in the rats treated with both PAG 
and AOA in combination is likely to be related to pressure-
diuresis and natriuresis phenomenon as MAP increased in 
rats with this combination therapy.16 These data suggest that 
the hypertensive response to chronic H2S deficiency may be 
primarily due to its’ effect on systemic vascular resistance. 
However, as the renal excretory function could be influenced 
by the systemic effects of these inhibitors, it may not be pos-
sible to determine the specific functional effects of CGL and 
CBS inhibition in the kidney from the present results. It was 
also reported23 that acute administration of PAG and AOA in 
combination directly in the kidney caused reductions in GFR, 
urine flow, and sodium excretion without appreciable change 
in RBF or systemic arterial pressure. Although these renal 
excretory changes to acute administration of CGL and CBS 
inhibitors23 seem apparently contradictory with the findings 
in the present chronic study, it should be noted here that these 
responses to H2S deficiency in both these studies were only 
observed when these inhibitors were administered in combi-
nation but not in alone. Thus the findings in these studies (23 
and the current study) are supportive of the conclusion that 
endogenous H2S level is interdependently maintained by the 
activity of these enzymes.
In the present study, it was observed that chronic PAG treat-
ment  enhanced  CGL  immune-expression  as  well  as  protein 
  levels in the renal tissue that was slightly reversed but remained 
high at significant level in rats treated with combination therapy 
as determined by both immune-staining (Figure 5) and west-
ern blot analysis (Figure 7a). The reason for such enhancement 
of CGL protein expression during chronic PAG administration 
with or without AOA treatment is not yet clearly understood. 
However, it seems that inhibition of CGL enzymatic activity by 
PAG caused a compensatory stimulation of the synthesis of it 
own enzyme proteins. Such up-regulation of specific enzyme 
protein expressions in response to chronic treatment with its 
inhibitor agent may not be entirely unexpected. For example, 
angiotensinogen  mRNA  was  also  seen  up-regulated  during 
chronic treatment with angiotensin converting enzyme inhibi-
tors.31 However, chronic AOA treatment alone in the present 
study did not show any marked changes in the protein levels of 
CBS or CGL in the renal tissue (Figures 6 and 7b). It is inter-
esting to note that the immunohistochemistry analysis of renal 
tissues in the present study demonstrated that CGL was mainly 
located in renal vasculature as well distal nephron segments 
while CBS was located only in the proximal tubules. These data 
demonstrate  distinctive  tubular  locations  of  CBS  (proximal 
tubule) and CGL (distal tubules and collecting ducts) that war-
rants further experiments to determine the differential regula-
tion of tubular function by these H2S producing enzymes.
In conclusion, the findings in the present investigation indi-
cate that the functional deficiency in the activity of one H2S 
producing enzyme could be compensated by the activity of the 
other to maintain the endogenous H2S production level. The 
present data demonstrate that chronic H2S deficiency caused 
increases in vascular resistance leading to renal vasoconstric-
tion and systemic hypertension. These data suggest that the 
hypertensive response to chronic H2S deficiency may be prima-
rily due to its effect of increasing systemic vascular resistance.
acknowledgments: The authors are grateful to alexander Castillo, BS and 
Camille Bourgeois, BS for their excellent technical assistance in this study. 
This study was supported by national Heart Lung and Blood Institute Grant 
HL-66432 (D.S.a.M.), american Heart association (09BGIa2280440; M.C.P.) 
and Tulane Enhancement Fund (D.S.a.M.).
Disclosure: The authors declared no conflict of interest.
1.  Tang CS, Li XH, Du JB. Hydrogen sulfide as a new endogenous gaseous 
transmitter in the cardiovascular system. Curr Vasc Pharmacol 2006; 4:17–22.
2.  Hosoki R, Matsuki N, Kimura H. The possible role of hydrogen sulfide as an 
endogenous smooth muscle relaxant in synergy with nitric oxide. Biochem 
Biophys Res Commun 1997; 237:527–531.
3.  Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, Meng Q, Mustafa AK, Mu W, Zhang S, 
Snyder SH, Wang R. H2S as a physiologic vasorelaxant: hypertension in mice with 
deletion of cystathionine gamma-lyase. Science 2008; 322:587–590.
4.  Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous 
neuromodulator. J Neurosci 1996; 16:1066–1071.
5.  Shibuya N, Tanaka M, Yoshida M, Ogasawara Y, Togawa T, Ishii K, Kimura H. 
3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound 
sulfane sulfur in the brain. Antioxid Redox Signal 2009; 11:703–714.
6.  Zhao W, Ndisang JF, Wang R. Modulation of endogenous production of H2S in rat 
tissues. Can J Physiol Pharmacol 2003; 81:848–853.
7.  Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H(2)S as a novel 
endogenous gaseous K(ATP) channel opener. EMBO J 2001; 20:6008–6016.
8.  Zhao W, Wang R. H(2)S-induced vasorelaxation and underlying cellular and 
molecular mechanisms. Am J Physiol Heart Circ Physiol 2002; 283:H474–H480.
4
a
b
1.5
1.0
0.5
0.0
3
2
C
G
L
/
β
-
a
c
t
i
n
 
p
r
o
t
e
i
n
 
l
e
v
e
l
s
 
r
a
t
i
o
C
B
S
/
β
-
a
c
t
i
n
 
p
r
o
t
e
i
n
 
l
e
v
e
l
s
 
r
a
t
i
o
1
0
Control PAGA OA PAG + AOA
Control PAGA OA PAG + AOA
CGL
β-Actin
CBS
β-Actin
* #
*
Figure 7 | representative western blots showing CGL (upper panel; a) 
and CBS (Lower panel; b) protein levels in whole kidney samples (n = 4 in 
each cases) from the control rats and the rats treated with either PaG (d l -
propargylglycine; CGL inhibitor), aOa (aminooxyacetic acid; CBS inhibitor) or 
combination of both (PaG + aOa). Densitometric analyses were done against 
β actin, used as loading control. Control levels were defined as the unit. 
*P < 0.01 vs. control, #P < 0.01 vs. PaG. CBS, cystathionine β-synthase; CGL, 
cystathionine γ-lyase.AMERICAN JOURNAL OF HYPERTENSION | VOLuME 25 nuMBEr 1 | January 2012     81
original contributions Hydrogen Sulfide and Systemic Blood Pressure
9.  Cheng Y, Ndisang JF, Tang G, Cao K, Wang R. Hydrogen sulfide-induced relaxation 
of resistance mesenteric artery beds of rats. Am J Physiol Heart Circ Physiol 2004; 
287:H2316–H2323.
10.  Zhong G, Chen F, Cheng Y, Tang C, Du J. The role of hydrogen sulfide generation 
in the pathogenesis of hypertension in rats induced by inhibition of nitric oxide 
synthase. J Hypertens 2003; 21:1879–1885.
11.  Ishii I, Akahoshi N, Yamada H, Nakano S, Izumi T, Suematsu M. Cystathionine 
gamma-Lyase-deficient mice require dietary cysteine to protect against acute 
lethal myopathy and oxidative injury. J Biol Chem 2010; 285:26358–26368.
12.  Kulkarni KH, Monjok EM, Zeyssig R, Kouamou G, Bongmba ON, Opere CA, Njie YF, 
Ohia SE. Effect of hydrogen sulfide on sympathetic neurotransmission and 
catecholamine levels in isolated porcine iris-ciliary body. Neurochem Res 2009; 
34:400–406.
13.  Han Y, Qin J, Chang X, Yang Z, Bu D, Du J. Modulating effect of hydrogen sulfide on 
gamma-aminobutyric acid B receptor in recurrent febrile seizures in rats. Neurosci 
Res 2005; 53:216–219.
14.  Yan H, Du J, Tang C. The possible role of hydrogen sulfide on the pathogenesis of 
spontaneous hypertension in rats. Biochem Biophys Res Commun 2004;  
313:22–27.
15.  Matavelli LC, Kadowitz PJ, Navar LG, Majid DS. Renal hemodynamic and excretory 
responses to intra-arterial infusion of peroxynitrite in anesthetized rats. Am J 
Physiol Renal Physiol 2009; 296:F170–F176.
16.  Majid DS, Godfrey M, Navar LG. Pressure natriuresis and renal medullary blood 
flow in dogs. Hypertension 1997; 29:1051–1057.
17.  Stipanuk MH, Beck PW. Characterization of the enzymic capacity for cysteine 
desulphhydration in liver and kidney of the rat. Biochem J 1982; 206:267–277.
18.  Siegel LM. A direct microdetermination for sulfide. Anal Biochem 1965; 11: 
126–132.
19.  Ishigami M, Hiraki K, Umemura K, Ogasawara Y, Ishii K, Kimura H. A source of 
hydrogen sulfide and a mechanism of its release in the brain. Antioxid Redox 
Signal 2009; 11:205–214.
20.  Bruinenberg PG, De Roo G, Limsowtin G. Purification and characterization of 
cystathionine (gamma)-lyase from lactococcus lactis subsp. cremoris SK11: 
Possible role in flavor compound formation during cheese maturation. Appl 
Environ Microbiol 1997; 63:561–566.
21.  Skovby F, Kraus JP, Rosenberg LE. Biosynthesis of human cystathionine beta-
synthase in cultured fibroblasts. J Biol Chem 1984; 259:583–587.
22.  Zhang C, Du J, Bu D, Yan H, Tang X, Tang C. The regulatory effect of hydrogen 
sulfide on hypoxic pulmonary hypertension in rats. Biochem Biophys Res Commun 
2003; 302:810–816.
23.  Xia M, Chen L, Muh RW, Li PL, Li N. Production and actions of hydrogen sulfide, 
a novel gaseous bioactive substance, in the kidneys. J Pharmacol Exp Ther 2009; 
329:1056–1062.
24.  Furchgott RF, Jothianandan D. Endothelium-dependent and -independent 
vasodilation involving cyclic GMP: relaxation induced by nitric oxide, carbon 
monoxide and light. Blood Vessels 1991; 28:52–61.
25.  Kimura H. Hydrogen sulfide induces cyclic AMP and modulates the NMDA 
receptor. Biochem Biophys Res Commun 2000; 267:129–133.
26.  Lim JJ, Liu YH, Khin ES, Bian JS. Vasoconstrictive effect of hydrogen sulfide involves 
downregulation of cAMP in vascular smooth muscle cells. Am J Physiol, Cell Physiol 
2008; 295:C1261–C1270.
27.  Wang R. Hydrogen sulfide: a new EDRF. Kidney Int 2009; 76:700–704.
28.  Du J, Hui Y, Cheung Y, Bin G, Jiang H, Chen X, Tang C. The possible role of hydrogen 
sulfide as a smooth muscle cell proliferation inhibitor in rat cultured cells. Heart 
Vessels 2004; 19:75–80.
29.  Yang G, Sun X, Wang R. Hydrogen sulfide-induced apoptosis of human aorta 
smooth muscle cells via the activation of mitogen-activated protein kinases and 
caspase-3. Faseb J 2004; 18:1782–1784.
30.  Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD. 
Paracrine regulation of the renal microcirculation. Physiol Rev 1996; 76:425–536.
31.  Peeler TC, Baker KM, Esmurdoc CF, Chernin MI. Angiotensin converting enzyme 
inhibition in Dahl salt-sensitive rats. Mol Cell Biochem 1991; 104:45–50.